ARBs (angiotensin receptor blockers) are used in heart failure because they block a hormone that forces the heart to work harder, retain fluid, and gradually damage itself. By interrupting this process, ARBs reduce hospitalizations, slow structural damage to the heart, and in some cases lower the risk of death. They’re most commonly prescribed when patients can’t tolerate ACE inhibitors, which work through a similar but slightly different mechanism.
How ARBs Protect a Failing Heart
To understand why ARBs help, you need to know what they’re blocking. Your body has a hormone system called RAAS that regulates blood pressure and fluid balance. When your kidneys sense low blood flow, they trigger a chain reaction that produces a powerful hormone called angiotensin II. In a healthy person, this system kicks in temporarily and helps maintain blood pressure. In heart failure, it stays chronically activated, and that’s where the damage begins.
Angiotensin II raises blood pressure by tightening blood vessels and increasing resistance throughout the circulatory system. It also tells your kidneys to hold onto sodium and water, increasing blood volume. For a heart that’s already struggling to pump effectively, this extra pressure and fluid volume is like asking someone with a broken leg to carry a heavier load. The heart has to work harder with every beat.
The long-term effects are even worse. Chronically elevated angiotensin II promotes the growth and thickening of heart muscle cells, triggers inflammation, damages blood vessel linings, and causes scarring (fibrosis) in heart tissue. Over months and years, this process reshapes the heart’s chambers, making them stiffer, larger, and less efficient. Cardiologists call this “cardiac remodeling,” and it’s a major driver of heart failure progression.
ARBs work by sitting on the specific receptor (called AT1) where angiotensin II does most of its damage. The hormone is still produced, but it can’t deliver its harmful signals. Blood vessels relax, the kidneys release excess sodium and water, and the constant stress on the heart eases. Over time, this also slows or partially reverses the structural damage to the heart.
Evidence From Major Clinical Trials
Two large trials established ARBs as effective heart failure treatments. The Val-HeFT trial tested valsartan against a placebo in patients already receiving standard heart failure therapy. Overall mortality was similar between groups, but the combined outcome of death and hospitalization dropped by 13.2%. The biggest difference was in heart failure hospitalizations specifically: 18.2% of patients on placebo were hospitalized compared to 13.8% on valsartan.
The CHARM trials, which tested candesartan, showed even stronger results. Cardiovascular death or heart failure hospitalization occurred in 35.7% of patients on candesartan versus 41.3% on placebo. Candesartan reduced cardiovascular deaths by 16% and heart failure hospitalizations by 24%. All-cause mortality also dropped significantly: 28.0% in the candesartan group versus 31.0% on placebo.
Animal research has helped explain the structural benefits. In one study using a rat model of heart failure caused by reduced blood flow, the ARB losartan cut left atrial fibrosis roughly in half (4.3% scarred tissue versus 8.1% in untreated animals). The treated animals also showed better-preserved pumping function and less enlargement of the heart chambers. These findings align with what clinicians see in patients: ARBs don’t just manage symptoms, they slow the physical deterioration of the heart.
Why ARBs Instead of ACE Inhibitors
ACE inhibitors were the first drugs to target the RAAS system in heart failure, and they remain a cornerstone of treatment. They work one step earlier in the chain, preventing the creation of angiotensin II rather than blocking its receptor. The catch is that ACE inhibitors also interfere with the breakdown of another substance called bradykinin. Bradykinin buildup is responsible for the persistent dry cough that affects a significant number of patients on ACE inhibitors, and in rare cases, it can cause dangerous swelling of the throat and face (angioedema).
ARBs don’t affect bradykinin at all. They leave that pathway untouched and simply block angiotensin II at its destination. This makes them a practical alternative for patients who develop a cough or swelling on ACE inhibitors. Withdrawal rates due to side effects are lower with ARBs than with ACE inhibitors.
Where ARBs Fit in Current Treatment
Current guidelines from the American College of Cardiology position ARBs as one layer in a multi-drug approach to heart failure with reduced pumping function (HFrEF). The preferred medication in this drug class is now actually a combination drug called sacubitril/valsartan, which pairs an ARB with a second compound that enhances the heart’s natural protective hormones. This combination carries the highest recommendation level (Class I) for reducing hospitalizations and cardiovascular death.
In practice, many patients start on an ACE inhibitor or a standalone ARB and then transition to sacubitril/valsartan once they’re stable. That transition requires a 36-hour gap between stopping the old medication and starting the new one, which takes some planning but is straightforward for most outpatients.
For patients who can’t tolerate sacubitril/valsartan or ACE inhibitors, a standalone ARB remains a well-supported option. The three ARBs with the most evidence in heart failure are candesartan, valsartan, and losartan. Each starts at a low dose and is gradually increased toward a target: candesartan from 4 to 8 mg daily up to 32 mg daily, valsartan from 20 to 40 mg twice daily up to 160 mg twice daily, and losartan from 25 to 50 mg daily up to 50 to 150 mg daily.
Side Effects and Monitoring
Because ARBs reduce the pressure inside the kidneys’ filtering units, they can cause a temporary bump in creatinine (a marker of kidney function). A rise of up to 20% is generally considered a normal, expected response rather than a sign of kidney damage. Your care team will typically check kidney function and potassium levels within days to two weeks of starting the medication or changing the dose. Once you’re stable, monitoring drops to roughly every six months.
Elevated potassium is the other key concern. By blocking aldosterone’s effects, ARBs reduce the kidney’s ability to excrete potassium. This is usually manageable but requires monitoring, especially if you’re also taking other medications that raise potassium levels. ARBs are generally avoided in people with bilateral renal artery stenosis (narrowing of the arteries feeding both kidneys), since these patients depend heavily on angiotensin II to maintain kidney filtration. Blocking it in that setting can cause a sharp decline in kidney function. Pregnancy is an absolute contraindication, as ARBs can cause serious harm to a developing fetus.